Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01616862 · ClinicalTrials.gov registry record

The Carrier Rates of Pseudomonas Aeruginosa in Family Members of Children With Cystic Fibrosis

A clinical trial of Cystic Fibrosis and Pseudomonas Aeruginosa, sponsored by Zafer Soultan.

Completed
Registry status
53
Enrollment target
1
Study location

NCT01616862 is a study of Cystic Fibrosis and Pseudomonas Aeruginosa that has completed, run by Zafer Soultan. The registered enrollment target is 53 participants, below the 179-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (70% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01616862, a study of Cystic Fibrosis and Pseudomonas Aeruginosa, has completed, sponsored by Zafer Soultan.

COMPLETED
Registry status
53 participants
Enrollment target
1
Study location

Study Summary

Pseudomonas aeruginosa (Pa) is the bacterium that causes one of the most consequential lung infections in people with CF. Many young children do not have Pa in their lungs but will become infected as they get older. The investigators want to learn more about how Pa is passed from person to person, especially to someone with Cystic Fibrosis (CF).

Study Locations (1)

New York

  • SUNY Upstate Medical University - Syracuse

Trial Details

FieldValue
Enrollment Target 53 participants
Start Date 2012-02
Est. Completion 2013-08

Sponsor

Zafer Soultan

1 total trials

What the Registry Record Tells You About NCT01616862

The ClinicalTrials.gov registry entry for NCT01616862 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 179-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (70% lower). The listed sponsor is Zafer Soultan, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Cystic Fibrosis appearing as the primary indexed condition, and to 0 interventions.

NCT01616862 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT01616862 about?

NCT01616862 is a clinical study titled "The Carrier Rates of Pseudomonas Aeruginosa in Family Members of Children With Cystic Fibrosis". Pseudomonas aeruginosa (Pa) is the bacterium that causes one of the most consequential lung infections in people with CF. Many young children do not have Pa in their lungs but will become infected as they get older. The investigators want to learn more about how Pa is passed from person to person, e...

What is the current status of trial NCT01616862?

This trial is currently completed. The enrollment target is 53 participants. The study started on 2012-02. Estimated completion is 2013-08.

What conditions does trial NCT01616862 study?

This clinical trial studies the following conditions: Cystic Fibrosis, Pseudomonas Aeruginosa.

Who is sponsoring clinical trial NCT01616862?

This trial is sponsored by Zafer Soultan, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01616862 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cystic Fibrosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.